Last reviewed · How we verify
Amnio-Maxx® Dual Layer Amnion Patch
Amnio-Maxx® Dual Layer Amnion Patch is a biologic product developed by Royal Biologics for use in surgical procedures to promote tissue repair and regeneration. It is derived from amniotic membrane and is designed to provide a barrier and support for healing. The product is not FDA-approved but is used off-label for various surgical applications. Its mechanism involves the release of growth factors and cytokines that facilitate wound healing and reduce inflammation. Despite its potential benefits, there is limited clinical data on its efficacy and safety, and it is important to consider the risks and benefits before use.
At a glance
| Generic name | Amnio-Maxx® Dual Layer Amnion Patch |
|---|---|
| Sponsor | Royal Biologics |
| Drug class | Biologic tissue graft |
| Target | Wound healing and tissue regeneration |
| Modality | Biologic |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Pipeline indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Amnio-Maxx® Dual Layer Amnion Patch CI brief — competitive landscape report
- Amnio-Maxx® Dual Layer Amnion Patch updates RSS · CI watch RSS
- Royal Biologics portfolio CI